Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Compass Therapeutics (CMPX) Return on Capital Employed (2023 - 2025)

Compass Therapeutics' Return on Capital Employed history spans 3 years, with the latest figure at 0.34% for Q4 2025.

  • For Q4 2025, Return on Capital Employed rose 7.0% year-over-year to 0.34%; the TTM value through Dec 2025 reached 0.34%, up 7.0%, while the annual FY2025 figure was 0.44%, 3.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.34% at Compass Therapeutics, up from 0.44% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.32% in Q4 2023 and bottomed at 0.62% in Q2 2025.
  • The 3-year median for Return on Capital Employed is 0.37% (2024), against an average of 0.42%.
  • The largest YoY upside for Return on Capital Employed was 7bps in 2025 against a maximum downside of -25bps in 2025.
  • A 3-year view of Return on Capital Employed shows it stood at 0.32% in 2023, then fell by -29bps to 0.42% in 2024, then increased by 17bps to 0.34% in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Return on Capital Employed are 0.34% (Q4 2025), 0.44% (Q3 2025), and 0.62% (Q2 2025).